NCT01130818 - First-in-Human Single Ascending Dose of GLPG0492 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

August 31, 2010

Study Completion Date

September 30, 2010

Conditions

Healthy

Interventions

DRUG

GLPG0492

single ascending doses, oral solution (25 to max. 120 mg/intake, 10 to 200 mg/mL)

DRUG

placebo

single dose, oral solution

DRUG

GLPG0492

single dose, solid formulation, 50 mg (2\*25 mg/capsule), fasting

DRUG

GLPG0492

single dose, solid formulation, 50 mg (2\*25 mg/capsule), after high fat breakfast

Trial Locations (1)

SGS Stuivenberg, Antwerp